JelloX Biotech Inc., a Taiwan-based startup at the forefront of cancer pathology, is announcing it will open a lab in the Discovery Oasis biotechnology space in Phoenix, Arizona.

Forecasts show cancer's global footprint expanding sharply, with annual case counts expected to rise 20% by 2030 and swell by 75% by mid-century, according to Statista. Meanwhile, Precedence Research ...

The following is a summary of "Novel devices and biomarkers in screening for esophageal squamous cell cancer," published in ...

A kind of cancer that strikes the throat is one of the fastest growing among men and it often comes after much heartburn.

The American doctor has revealed that enigmatic DNA circles are present in more than half of patients with highly aggressive ...

Roswell Park Comprehensive Cancer Center achieved textbook outcomes for 90% of 150 consecutive robot-assisted, minimally ...

Less than one-quarter of oncologists surveyed indicated that every one of their patients with advanced gastric or gastroesophageal junction cancers received biomarker testing consistent with practice ...

Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, April 14, 2025 /PRNewswire/ -- ...

On March 5, 2025, the FDA cleared an investigational new drug application for CTD402, a CD7-targeted universal CAR T-cell therapy, for the treatment of pediatric and adult patients with ...

Here is a roundup of March 2025 U.S. FDA approvals across cancer subtypes, including prostate, bladder and gastrointestinal ...

The FDA approved several therapies in oncology in the month of March 2025. These drugs included treatments for ...

1Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas. Search for other works by this author on: 1Department of Investigational Cancer ...